- Inhibits a wide range of oral pathogens
- Competitively blocks binding of S. pyogenes to human cells
- Epidemiological studies support the protective role BLIS K12™ plays in preventing tonsillitis and ear infections
- Granted no objection GRAS status (Generally Recognized as Safe)
- 30 Lozenges
- Blister Packs and Box
- 2.5-5b CFU
- Shelf-stable, 24 months